STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOPH
  4. [Form 4] SOPHiA GENETICS SA Insider Trading Activity

SOPHiA GENETICS (SOPH) CSO granted 82,335 options and 56,468 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 82,335 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. He also received 56,468 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are awards, not open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Puylaert Kevin
Role Chief Sales Officer
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 82,335 $0.00 --
Grant/Award Ordinary Shares 56,468 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 82,335 shares (Direct); Ordinary Shares — 56,468 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Stock options granted 82,335 options Right to buy ordinary shares at $5.04, grant on April 2, 2026
Option exercise price $5.04 per share Exercise price for 82,335 options expiring April 2, 2036
RSUs granted 56,468 RSUs Restricted stock units under 2021 Equity Incentive Plan
RSU vesting start 25% on April 2, 2027 Initial vesting date for RSU grant
RSU remaining vesting 75% through April 2, 2030 Vests in equal quarterly installments, service-based
Option vesting schedule 25% on April 2, 2027 Remainder vests in equal monthly installments through April 2, 2030
Options expiration April 2, 2036 Final expiration date of 82,335 share options
Shares following RSU grant 56,468 shares Total ordinary shares reported following RSU acquisition entry
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
vesting financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
share option financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
exercisable financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Puylaert Kevin
(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12
(Street)
ROLLE1180
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Sales Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/02/2026A56,468(1)A$056,468D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$5.0404/02/2026A82,335 (2)04/02/2036Ordinary Shares82,335$082,335D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did SOPHiA GENETICS (SOPH) disclose in this Form 4 filing?

SOPHiA GENETICS disclosed that Chief Sales Officer Kevin Puylaert received new equity awards, including stock options and restricted stock units. These grants are compensation-related and do not involve any open-market buying or selling of the company’s shares by the executive.

How many stock options did Kevin Puylaert receive from SOPHiA GENETICS (SOPH)?

Kevin Puylaert received 82,335 stock options, each giving the right to buy one ordinary share at $5.04 per share. These options expire on April 2, 2036 and vest over time, starting in 2027 and continuing monthly through 2030.

What are the terms of the restricted stock units granted to SOPHiA GENETICS (SOPH) executive Kevin Puylaert?

He received 56,468 restricted stock units (RSUs), each representing one ordinary share, under the 2021 Equity Incentive Plan. Twenty-five percent vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.

Did the SOPHiA GENETICS (SOPH) Form 4 show any stock sales or purchases by Kevin Puylaert?

The filing shows no open-market stock purchases or sales by Kevin Puylaert. All reported transactions are compensation grants of stock options and restricted stock units, both recorded at a transaction price of $0.00 per share for reporting purposes.

When do Kevin Puylaert’s stock options at SOPHiA GENETICS (SOPH) vest and become exercisable?

The share options vest as to 25% on April 2, 2027, then continue vesting in equal monthly installments through April 2, 2030. He must remain in service with the company through each vesting date for the corresponding portion to become exercisable.

What conditions apply to Kevin Puylaert’s RSU grant at SOPHiA GENETICS (SOPH)?

Each RSU represents a contingent right to receive one ordinary share, subject to his continued service with SOPHiA GENETICS. Vesting occurs 25% on April 2, 2027, and the remaining 75% in equal quarterly installments through April 2, 2030.